Healthcare / Health Information ServicesNasdaqGS
$1.39
+0.01 (+0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-20.8M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-72.4%
↓Gross Margin
48.7%
↑Debt/Equity
0.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+19.9%
FCF CAGR
—
FCF margin
-6.7%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $311.1M · net income $-178.0M · FCF $-20.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $311.1M | $311.1M | $306.6M | $295.9M | $276.2M | $241.9M | $188.8M | $154.9M | $112.6M | $73.1M |
| Net Income | $-178.0M | $-178.0M | $-69.5M | $-118.1M | $-137.4M | $-153.2M | $-115.0M | $-60.1M | $-62.0M | $-47.0M |
| EBITDA | $-102.5M | $-102.5M | $-10.7M | $-57.8M | $-91.7M | $-106.1M | $-77.4M | $-45.7M | $-52.7M | $-39.6M |
| EPS | -2.55 | -2.55 | -1.15 | -2.09 | -2.63 | -3.23 | -2.91 | -12.86 | — | — |
| Gross Margin | 48.7% | 48.7% | 45.9% | 44.5% | 48.2% | — | — | — | — | — |
| Operating Margin | -13.7% | -13.7% | -18.8% | -33.8% | -50.7% | -59.4% | -50.9% | -35.4% | -53.4% | -62.3% |
| Net Margin | -57.2% | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | -60.9% | -38.8% | -55.1% | -64.4% |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.70 | 0.70 | 1.10 | 0.68 | 0.58 | 0.35 | 0.61 | 0.24 | -0.05 | — |
| Current Ratio | 1.69 | 1.69 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-20.8M | $-20.8M | $-1.8M | $-47.4M | $-52.7M | $-33.6M | $-33.9M | $-34.2M | $-42.4M | $-39.3M |
| Returns | ||||||||||
| ROE | -72.4% | -72.4% | -19.0% | -32.2% | -32.3% | -29.3% | -41.7% | -30.0% | 16.5% | 18.1% |
| Valuation | ||||||||||
| P/B | 0.40 | 0.40 | 1.22 | 1.47 | 1.37 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 1.5% | 1.5% | 3.6% | 7.1% | — | 28.1% | 21.9% | 37.6% | 54.0% | — |
| EPS Growth | -121.7% | -121.7% | 45.0% | 20.5% | — | -11.0% | 77.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-63.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.15 → -2.55
Residual
-63.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.